Sweet Smell Of Success For Destiny's Anti-MRSA Nasal Gel
Stock Soars On Phase IIb Data
Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.
You may also be interested in...
ContraFect’s Path Forward Gets Murky With Exebacase Trial Failure
The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.
Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19
The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip.
Less Is More: Destiny Phase IIb Trial Population Reduced
Destiny’s Phase IIb clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections got a boost from trial protocol amendments agreed with the FDA.